 |
|
|
 |
|
Drug Can Slow Bone Loss in Prostate Cancer Patients
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 | 3 Based on the findings, the team advised that alendronate treatment be prescribed for prostate cancer patients at the same time ADT is commenced.
Dr. Matthew Smith, director of genitourinary medical oncology at Massachusetts General Hospital Cancer Center, Boston, said that while the current study is "beautiful work," more focused research is needed, given that fracture risk is an "underappreciated problem."
"There have already been a number of studies looking at drugs to increase bone density," Smith said. "So this is not a criticism of this study, but I have to say that, really, what we need now are large long-term studies that look at how to prevent fractures in men. We want high-level evidence for any intervention that we do, and we haven't had that so far."
Text Continues Below

More information
There's more on osteoporosis in men at the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 9/19/2008
|
 |

SOURCES: Neil M. Resnick, M.D., professor, medicine, department of geriatrics, University of Pittsburgh; Matthew Smith, M.D., Ph.D., director, genitourinary medical oncology, Massachusetts General Hospital Cancer Center, Boston; Sept. 20, 2008, Journal of Clinical Oncology
|